Gefitinib Versus Pemetrexed for Previously Treated NSCLC Patients
To compare the efficacy of gefitinib versus pemetrexed as second-line chemotherapy for patients with previous treated non-small cell lung cancer
Previous Treated Metastatic Non-small Cell Lung Cancer
DRUG: Gefitinib|DRUG: Pemetrexed
Overall response rate, 5 years
Progression free survival, 5years
Number of participants with adverse events, 5years
To compare the efficacy of gefitinib versus pemetrexed as second-line chemotherapy for patients with previous treated non-small cell lung cancer